[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA006445B9 - Кристаллы, содержащие соль яблочной кислоты n-[2-(диэтиламино)этил]-5-[(5-фторо-2-оксо-1,2-дигидро-3h-индол-3-илиден)метил]-2,4-диметил-1h-пиррол-3-карбоксамида, способы их получения и их композиции - Google Patents

Кристаллы, содержащие соль яблочной кислоты n-[2-(диэтиламино)этил]-5-[(5-фторо-2-оксо-1,2-дигидро-3h-индол-3-илиден)метил]-2,4-диметил-1h-пиррол-3-карбоксамида, способы их получения и их композиции

Info

Publication number
EA006445B9
EA006445B9 EA200400183A EA200400183A EA006445B9 EA 006445 B9 EA006445 B9 EA 006445B9 EA 200400183 A EA200400183 A EA 200400183A EA 200400183 A EA200400183 A EA 200400183A EA 006445 B9 EA006445 B9 EA 006445B9
Authority
EA
Eurasian Patent Office
Prior art keywords
ylidene
carboxamide
diethylamino
pyrrole
oxo
Prior art date
Application number
EA200400183A
Other languages
English (en)
Other versions
EA006445B1 (ru
EA200400183A1 (ru
Inventor
Майкл ХОЛИ
Томас Дж. Флек
Стивен П. Прескотт
Марк Т. Малоуни
Original Assignee
Фармация Энд Апджон Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23211067&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA006445(B9) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Фармация Энд Апджон Компани filed Critical Фармация Энд Апджон Компани
Publication of EA200400183A1 publication Critical patent/EA200400183A1/ru
Publication of EA006445B1 publication Critical patent/EA006445B1/ru
Publication of EA006445B9 publication Critical patent/EA006445B9/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Согласно настоящему изобретению предложены кристаллы и их композиции, причем данные кристаллы включают соль яблочной кислоты N-[2-(диэтиламино)этил]-5-[(5-фторо-1,2-дигидро-2-оксо-3H-индол-3-илиден)метил]-2,4-диметил-1Н-пиррол-3-карбоксамида. Кроме того, описаны способы получения таких кристаллов.
EA200400183A 2001-08-15 2002-08-13 Кристаллы, содержащие соль яблочной кислоты n-[2-(диэтиламино)этил]-5-[(5-фторо-2-оксо-1,2-дигидро-3h-индол-3-илиден)метил]-2,4-диметил-1h-пиррол-3-карбоксамида, способы их получения и их композиции EA006445B9 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31235301P 2001-08-15 2001-08-15
PCT/US2002/025649 WO2003016305A1 (en) 2001-08-15 2002-08-13 Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole-3-ylidene) methyl]-2, 4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof

Publications (3)

Publication Number Publication Date
EA200400183A1 EA200400183A1 (ru) 2004-08-26
EA006445B1 EA006445B1 (ru) 2005-12-29
EA006445B9 true EA006445B9 (ru) 2017-02-28

Family

ID=23211067

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200400183A EA006445B9 (ru) 2001-08-15 2002-08-13 Кристаллы, содержащие соль яблочной кислоты n-[2-(диэтиламино)этил]-5-[(5-фторо-2-оксо-1,2-дигидро-3h-индол-3-илиден)метил]-2,4-диметил-1h-пиррол-3-карбоксамида, способы их получения и их композиции

Country Status (43)

Country Link
US (2) US20030069298A1 (ru)
EP (3) EP1419151B1 (ru)
JP (1) JP4159988B2 (ru)
KR (1) KR100639281B1 (ru)
CN (2) CN100439360C (ru)
AP (1) AP1660A (ru)
AR (1) AR036261A1 (ru)
AU (1) AU2002324684B2 (ru)
BG (1) BG108553A (ru)
BR (1) BR0211612A (ru)
CA (1) CA2455050C (ru)
CO (1) CO5550431A2 (ru)
CU (1) CU23713B7 (ru)
CY (1) CY1121552T1 (ru)
CZ (1) CZ2004196A3 (ru)
DK (2) DK3168218T3 (ru)
EA (1) EA006445B9 (ru)
EC (1) ECSP044975A (ru)
ES (3) ES2453164T3 (ru)
GE (1) GEP20063777B (ru)
HK (2) HK1066542A1 (ru)
HR (1) HRP20040112B1 (ru)
HU (1) HU229206B1 (ru)
IL (1) IL160097A0 (ru)
IS (1) IS7147A (ru)
MA (1) MA27058A1 (ru)
ME (1) ME00414B (ru)
MX (1) MXPA04001452A (ru)
MY (1) MY139383A (ru)
NO (1) NO326508B1 (ru)
NZ (1) NZ531232A (ru)
OA (1) OA12650A (ru)
PL (1) PL216524B1 (ru)
PT (2) PT1419151E (ru)
RS (1) RS53251B (ru)
SI (2) SI3168218T1 (ru)
SK (1) SK902004A3 (ru)
TN (1) TNSN04028A1 (ru)
TR (1) TR201900509T4 (ru)
TW (1) TWI269796B (ru)
UA (1) UA76483C2 (ru)
WO (1) WO2003016305A1 (ru)
ZA (1) ZA200400706B (ru)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA006445B9 (ru) 2001-08-15 2017-02-28 Фармация Энд Апджон Компани Кристаллы, содержащие соль яблочной кислоты n-[2-(диэтиламино)этил]-5-[(5-фторо-2-оксо-1,2-дигидро-3h-индол-3-илиден)метил]-2,4-диметил-1h-пиррол-3-карбоксамида, способы их получения и их композиции
TW200418836A (en) * 2002-09-10 2004-10-01 Pharmacia Italia Spa Formulations comprising an indolinone compound
DE602004028028D1 (de) * 2003-10-02 2010-08-19 Pharmacia & Upjohn Co Llc Salze und polymorphe formen einer pyrrolsubstituierten indolinonverbindung
US20060009510A1 (en) * 2004-07-09 2006-01-12 Pharmacia & Upjohn Company Llc Method of synthesizing indolinone compounds
ES2349798T3 (es) * 2004-07-22 2011-01-11 Eli Lilly And Company Hidrato variable cristalino de la sal hemisuccinato de (s)-6-(4-(2-((3-(9h-carbazol-4-iloxi)-2-hidroxipropil)amino)-2-metilpropil)fenoxi)-3-piridinocarboxamida.
US20080193448A1 (en) * 2005-05-12 2008-08-14 Pfizer Inc. Combinations and Methods of Using an Indolinone Compound
MX2008002415A (es) * 2005-09-19 2008-03-27 Pfizer Prod Inc Formas salinas solidas de una 2-indolinona sustituida con pirrol.
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
US20100256392A1 (en) * 2007-11-21 2010-10-07 Teva Pharmaceutical Industries Ltd. Polymorphs of sunitinib base and processes for preparation thereof
CA2699305A1 (en) * 2007-11-21 2009-05-28 Teva Pharmaceutical Industries Ltd. Polymorphs of sunitinib base and processes for preparation thereof
CA2709083A1 (en) * 2007-12-12 2009-06-18 Medichem S.A. Polymorphic forms of a 3-pyrrole substituted 2-indolinone
EP2090306A1 (en) 2008-02-13 2009-08-19 Ratiopharm GmbH Pharmaceutical compositions comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
EP2113248A1 (en) 2008-04-29 2009-11-04 Ratiopharm GmbH Pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-,4-dimethyl-1H-pyrrole-3-carboxamide
US20110112164A1 (en) * 2008-02-21 2011-05-12 Generics (Uk) Limited Novel polymorphs and processes for their preparation
EP2098521A1 (en) * 2008-03-06 2009-09-09 Ratiopharm GmbH Crystal forms of N-[2-(diethylamino) ethyl]-5-[fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrolle-3-carboxamide and methods for their prepparation
US20090247767A1 (en) * 2008-03-31 2009-10-01 Teva Pharmaceutical Industries Ltd. Processes for preparing sunitinib and salts thereof
KR20100135910A (ko) * 2008-04-16 2010-12-27 낫코 파마 리미티드 수니티닙 염기의 신규한 다형 형태
CA2725001C (en) 2008-05-23 2014-05-13 Jiangsu Chiatai Tianqing Pharmaceutical Co., Ltd. Dihydroindolone derivatives
WO2009150523A1 (en) * 2008-06-13 2009-12-17 Medichem, S.A. Process for preparing a 3-pyrrole substituted 2-indolinone malate salt
EP2138167A1 (en) 2008-06-24 2009-12-30 ratiopharm GmbH Pharmaceutical composition comprising N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
WO2009156837A2 (en) * 2008-06-26 2009-12-30 Medichem, S.A. Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt
AU2009269768A1 (en) * 2008-07-10 2010-01-14 Generics [Uk] Limited Processes for the preparation of crystalline forms of sunitinib malate
CN102164913A (zh) * 2008-07-24 2011-08-24 麦迪凯姆股份公司 一种3-吡咯替代的2-吲哚酮苹果酸盐的结晶体形式
CA2731605A1 (en) 2008-07-24 2010-01-28 Teva Pharmaceutical Industries Ltd. Sunitinib and salts thereof and their polymorphs
CA2734965A1 (en) * 2008-08-25 2010-03-04 Generics [Uk] Limited Novel crystalline form and processes for its preparation
US20110263670A1 (en) * 2008-08-25 2011-10-27 Vinayak Gore Novel polymorphs of sunitinib and processes for their preparation
WO2010041134A1 (en) * 2008-10-10 2010-04-15 Medichem, S.A. Process for preparing a 3-pyrrole subsituted 2-indolinone malate salt
EP2181991A1 (en) 2008-10-28 2010-05-05 LEK Pharmaceuticals D.D. Novel salts of sunitinib
EP2186809A1 (en) 2008-11-13 2010-05-19 LEK Pharmaceuticals D.D. New crystal form of sunitinib malate
EP2896618A1 (en) * 2009-01-02 2015-07-22 Hetero Research Foundation Polymorphs of sunitinib malate
TW201920110A (zh) 2009-01-16 2019-06-01 美商艾克塞里克斯公司 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
EP2255792A1 (en) 2009-05-20 2010-12-01 Ratiopharm GmbH Pharmaceutical compositions for N-[2-(Diethylamino)ethyl]5-[(fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene) methyl]-2,4-dimenthyl-1H-pyrrole-3-carboxamide
WO2011004200A1 (en) 2009-07-10 2011-01-13 Generics [Uk] Limited Novel pyrrole derivatives
CA2774634A1 (en) 2009-09-16 2011-03-24 Ranbaxy Laboratories Limited Salts of sunitinib
US20120271056A1 (en) * 2009-11-12 2012-10-25 Ranbaxy Laboratories Limited Process for the preparation of crystalline form i of l-malic acid salt of sunitinib
US8916716B2 (en) 2009-11-19 2014-12-23 Ranbaxy Laboratories Limited Process for the preparation of crystalline form II of L-malic acid salt of sunitinib
WO2011092664A1 (en) 2010-01-29 2011-08-04 Ranbaxy Laboratories Limited Crystalline forms of l-malic acid salt of sunitinib
WO2011100325A2 (en) 2010-02-09 2011-08-18 Sicor Inc. Polymorphs of sunitinib salts
WO2011104555A2 (en) 2010-02-25 2011-09-01 Generics [Uk] Limited Novel process
EP2542550A1 (en) 2010-03-04 2013-01-09 Ranbaxy Laboratories Limited Process for the direct preparation of malic acid salt of sunitinib
WO2011114246A1 (en) 2010-03-18 2011-09-22 Ranbaxy Laboratories Limited Process for the preparation of malic acid salt of sunitinib
WO2011128699A2 (en) 2010-04-16 2011-10-20 Generics [Uk] Limited Novel process
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
ES2724801T3 (es) 2011-04-19 2019-09-16 Pfizer Combinaciones de anticuerpos anti-4-1BB y anticuerpos inductores de ADCC para el tratamiento del cáncer
EP2828251B1 (en) 2012-03-23 2018-10-31 Laurus Labs Limited An improved process for the preparation of sunitinib and its acid addition salts thereof
PL399027A1 (pl) 2012-04-27 2013-10-28 Instytut Farmaceutyczny Sposób otrzymywania N-[2-(dietylamino)etylo]-5-formylo-2,4-dimetylo-1H-pirolo-3-karboksyamidu o wysokiej czystosci i jego zastosowanie do wytwarzania sunitynibu
CN105457021A (zh) 2012-05-04 2016-04-06 辉瑞公司 前列腺相关抗原及基于疫苗的免疫治疗疗法
US9278955B2 (en) 2013-10-18 2016-03-08 Sun Pharmaceutical Industries Limited Ascorbic acid salt of sunitinib
CA2838587A1 (en) 2013-10-18 2015-04-18 Hari Babu Matta Pure crystalline form ii of l-malic acid salt of sunitinib and processes for its preparation
WO2015063647A1 (en) 2013-11-01 2015-05-07 Pfizer Inc. Vectors for expression of prostate-associated antigens
CN104693187A (zh) * 2013-12-10 2015-06-10 安杰世纪生物科技（北京）有限公司 一种舒尼替尼L-苹果酸盐晶型λ及其制备方法
CN104744442B (zh) * 2013-12-25 2019-05-28 江苏豪森药业集团有限公司 苹果酸舒尼替尼的制备方法
RU2567535C1 (ru) * 2014-10-01 2015-11-10 Олег Ростиславович Михайлов КРИСТАЛЛИЧЕСКАЯ ε-МОДИФИКАЦИЯ N-[2-(ДИЭТИЛАМИНО)ЭТИЛ]-5-[(Z)-(5-ФТОР-1,2-ДИГИДРО-2-ОКСО-3Н-ИНДОЛ-3-ИЛИДЕН)МЕТИЛ]-2,4-ДИМЕТИЛ-1Н-ПИРРОЛ-3-КАРБОКСАМИД МАЛАТА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЕ ОСНОВЕ
CN105712979A (zh) * 2014-12-05 2016-06-29 广州白云山医药集团股份有限公司白云山制药总厂 一种苹果酸舒尼替尼晶型ⅰ的制备方法
EP3539536A1 (en) 2018-03-15 2019-09-18 MH10 Spolka z ograniczona odpowiedzialnoscia A pharmaceutical composition of sunitinib or its salt thereof in its polymorphic form i
WO2020216450A1 (en) 2019-04-25 2020-10-29 Synthon B.V. Pharmaceutical composition comprising amorphous sunitinib
AU2020257415A1 (en) * 2019-04-18 2021-11-11 Meter Health, Inc. Methods and compositions for treating respiratory arrhythmias
KR20240025990A (ko) 2022-08-19 2024-02-27 주식회사 스카이테라퓨틱스 무정형 수니티닙, 그 제조방법 및 이를 포함한 의약 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001037820A2 (en) * 1999-11-24 2001-05-31 Sugen, Inc. Ionizable indolinone derivatives and their use as ptk ligands
WO2001060814A2 (en) * 2000-02-15 2001-08-23 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL170330B1 (pl) 1990-10-15 1996-11-29 Pfizer Sposób wytwarzania nowych pochodnych indolu PL PL PL PL PL PL
IL100091A (en) * 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical preparations containing the physical form of [4] 5) Cyclopentyloxycarbyl (amino 1 methyl indole 3 methyl methyl [3 methoxybenzoyl [2 methylbenzole)
AU659311B2 (en) 1992-06-05 1995-05-11 Merck Sharp & Dohme Limited The sulphate salt of a substituted triazole, pharmaceutical compositions thereof, and their use in therapy
WO1994020505A1 (en) * 1993-03-12 1994-09-15 The Upjohn Company Crystalline ceftiofur free acid
US6329364B1 (en) 1994-08-31 2001-12-11 Eli Lilly And Company Crystalline form of dihydro-2,3-benzodiazepine derivative
DE19503966C2 (de) 1995-02-07 1998-07-02 Mack Chem Pharm Kristallmodifikation von 2,4-Diamino-6-hydroxymethylpteridin-Hydrobromid, Verfahren zu dessen Herstellung und dessen Verwendung
US5597663A (en) * 1995-05-30 1997-01-28 Motorola, Inc. Low temperature molten lithium salt electrolytes for electrochemical cells
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5673451A (en) * 1995-07-06 1997-10-07 Moore; James R. Instructional toothbrush
US20020045746A1 (en) 1995-12-11 2002-04-18 Barton Kathleen P. Eplerenone crystalline form
US20020038021A1 (en) 1995-12-11 2002-03-28 Barton Kathleen P. Eplerenone crystalline form exhibiting enhanced dissolution rate
US6066647A (en) 1996-07-29 2000-05-23 Pfizer Inc. Zwitterionic forms of trovafloxacin
TR199900298T2 (xx) 1996-08-14 1999-05-21 G.D. Searle &Co. 4-(5-Metil-3-fenilizoksazol-4-il) BenzenS�lfonamidin kristal halinde bi�imi.
WO1998029344A1 (fr) 1996-12-25 1998-07-09 Nippon Kayaku Kabushiki Kaisha Poudre de cisplatine fine et son procede de production
US5777185A (en) * 1997-09-09 1998-07-07 Laroche Industries Inc. Production of organic fluorine compounds
US6133305A (en) * 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
US6012678A (en) * 1998-01-26 2000-01-11 The Boeing Company Galley vacuum waste disposal system
US6225474B1 (en) 1998-06-19 2001-05-01 Teijin Limited Polymorphs of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and method of producing the same
DE69906152T2 (de) * 1998-12-17 2004-02-12 F. Hoffmann-La Roche Ag 4-alkenyl (und alkinyl)oxoindole als inhibitoren cyclinabhängiger kinasen, insbesondere cdk2
US6239141B1 (en) 1999-06-04 2001-05-29 Pfizer Inc. Trovafloxacin oral suspensions
US6316672B1 (en) 2001-01-31 2001-11-13 Grayson Walker Stowell Form a of fluoxetine hydrochloride
EA006445B9 (ru) 2001-08-15 2017-02-28 Фармация Энд Апджон Компани Кристаллы, содержащие соль яблочной кислоты n-[2-(диэтиламино)этил]-5-[(5-фторо-2-оксо-1,2-дигидро-3h-индол-3-илиден)метил]-2,4-диметил-1h-пиррол-3-карбоксамида, способы их получения и их композиции
US20110112164A1 (en) 2008-02-21 2011-05-12 Generics (Uk) Limited Novel polymorphs and processes for their preparation
WO2009156837A2 (en) 2008-06-26 2009-12-30 Medichem, S.A. Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001037820A2 (en) * 1999-11-24 2001-05-31 Sugen, Inc. Ionizable indolinone derivatives and their use as ptk ligands
WO2001060814A2 (en) * 2000-02-15 2001-08-23 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors

Also Published As

Publication number Publication date
CY1121552T1 (el) 2020-05-29
DK3168218T3 (en) 2019-01-14
NZ531232A (en) 2004-11-26
JP2005503386A (ja) 2005-02-03
BR0211612A (pt) 2004-08-24
RS53251B (sr) 2014-08-29
ES2453164T3 (es) 2014-04-04
GEP20063777B (en) 2006-03-27
HUP0700036A2 (en) 2008-10-28
SK902004A3 (sk) 2005-03-04
PT1419151E (pt) 2014-03-27
HRP20040112B1 (en) 2012-03-31
US20030069298A1 (en) 2003-04-10
IL160097A0 (en) 2004-06-20
CN100364991C (zh) 2008-01-30
HU229206B1 (en) 2013-09-30
AU2002324684B2 (en) 2006-10-05
TNSN04028A1 (fr) 2006-06-01
NO20041054L (no) 2004-03-12
BG108553A (bg) 2005-04-30
KR20040030074A (ko) 2004-04-08
ES2705063T3 (es) 2019-03-21
CN1789264A (zh) 2006-06-21
CU23713B7 (es) 2011-10-05
ME00414B (me) 2011-10-10
CZ2004196A3 (cs) 2005-01-12
EP1419151A1 (en) 2004-05-19
SI3168218T1 (sl) 2019-05-31
OA12650A (en) 2006-06-19
CN100439360C (zh) 2008-12-03
CU20040029A7 (es) 2008-03-14
SI1419151T1 (sl) 2014-04-30
PL216524B1 (pl) 2014-04-30
ECSP044975A (es) 2004-03-23
IS7147A (is) 2004-02-10
RS10304A (en) 2007-02-05
EP2332934B1 (en) 2017-03-01
EP3168218B1 (en) 2018-11-14
EA006445B1 (ru) 2005-12-29
EA200400183A1 (ru) 2004-08-26
AP1660A (en) 2006-09-09
PT3168218T (pt) 2019-01-11
CA2455050C (en) 2007-02-20
TR201900509T4 (tr) 2019-02-21
CN1543462A (zh) 2004-11-03
US7435832B2 (en) 2008-10-14
DK1419151T3 (da) 2014-03-31
HK1088008A1 (en) 2006-10-27
CO5550431A2 (es) 2005-08-31
EP3168218A1 (en) 2017-05-17
US20070191458A1 (en) 2007-08-16
CA2455050A1 (en) 2003-02-27
MA27058A1 (fr) 2004-12-20
HRP20040112A2 (en) 2004-06-30
MY139383A (en) 2009-09-30
MXPA04001452A (es) 2004-05-20
UA76483C2 (en) 2006-08-15
ZA200400706B (en) 2005-05-25
PL368317A1 (en) 2005-03-21
TWI269796B (en) 2007-01-01
NO326508B1 (no) 2008-12-15
HK1066542A1 (en) 2005-03-24
AP2004002976A0 (en) 2004-03-31
ES2623094T3 (es) 2017-07-10
EP1419151B1 (en) 2014-02-26
WO2003016305A1 (en) 2003-02-27
KR100639281B1 (ko) 2006-10-31
JP4159988B2 (ja) 2008-10-01
EP2332934A1 (en) 2011-06-15
AR036261A1 (es) 2004-08-25

Similar Documents

Publication Publication Date Title
EA006445B9 (ru) Кристаллы, содержащие соль яблочной кислоты n-[2-(диэтиламино)этил]-5-[(5-фторо-2-оксо-1,2-дигидро-3h-индол-3-илиден)метил]-2,4-диметил-1h-пиррол-3-карбоксамида, способы их получения и их композиции
IL189359A0 (en) Novel process for the synthesis of 5 - (4 - fluorophenyl) - 1 - [2 - ((2r, 4r)- 4 - hydroxy - 6 - oxo -tetrahydro - pyran - 2 - yl) - ethyl] - 2 - isopropyl- 4 - phenyl - 1h - pyrrole - 3 - carboxylic acid phenylamide
DE60218703D1 (de) (-)-1-(3,4-dichlorphenyl)-3-azabicyclo ä3.1.0ühexan, zusammensetzungen davon und verwendung als dopamin-wiederaufnahme-hemmer
UA93351C2 (ru) Производные фталазина kak ингибиторы parp
MX2007014892A (es) Formas polimorficas del ester etilico del acido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}- 1-metil-h-bencimidazol-5-carbonil)-piridin-2-il--amino]propionico .
GEP20115213B (en) Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists
AP1766A (en) Novel crystalline polymorphic forms of lercanidipine hydrochloride and process for their preparation.
WO2010010454A3 (en) Crystalline forms of a 3-pyrrole substituted 2-indolinone malate salt
NO20054071L (no) Polymorfer av pyrrol substituerte 2-indolinon protein kinase inhibitorer.
MXPA05006587A (es) Compuestos de tiazol como derivados de antagonistas del receptor de la integrina.
EP1406614A4 (en) CARVEDILOLPOLYMORPH
CY1115143T1 (el) Κρυσταλλοι που περιλαμβανουν μηλικο αλας του ν-[2-(διαιθυλαμινο)αιθυλο]-5-[(5-φθορο-1,2-διϋδρο-2-οξο-3η-ινδολ-3-ιλιδενο)μεθυλο]-2,4-διμεθυλο-1η-πυρρολο-3-καρβοξαμιδιου, διεργασιες παρασκευης αυτων και συνθεσεις αυτων
SG145573A1 (en) Intermediates useful in the synthesis of hiv-protease inhibitors and methods for preparing the same
TH69655A (th) ผลึกซึ่งประกอบด้วยเกลือของกรดมาลิคของ 3-ไพร์รอล ซับสทิทิวเทด 2-อินโดลิโนน และสารผสมของสารเหล่านี้
TW200740442A (en) Therapeutic agent for hypertension

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent
PD4A Registration of transfer of a eurasian patent in accordance with the succession in title